Triple-negative breast cancer (TNBC) remains the most aggressive form of breast cancer with a worse prognosis than other subtypes. Its high metastatic potential, limited availability of targeted therapies, and increased likelihood of being diagnosed at an advanced stage make it one of the most complex clinical challenges in breast cancer. Today, thanks to the advent of antibody-drug conjugates (ADCs), clinical outcomes have improved significantly. In this context, sacituzumab govitecan (SG) has been a true revolution. The case reported here illustrates how this therapeutic opportunity produced lasting clinical benefit in a highly complex patient with a triple neoplasm at presentation: inoperable locally advanced TNBC, operable colon cancer, and localized lung cancer. The chemorefractory patient (rapid progression of the first two lines of chemotherapy) received SG as a third-line treatment, showing a sustained response lasting more than 12 months and a significant benefit in terms of quality of life. This case highlights how a proper multidisciplinary approach can lead to a lasting clinical benefit from therapy. Deviating from the cases reported in clinical studies, it is important to underscore how, in this context, clinical choice prevailed. Given the locally advanced stage of the breast cancer, characterized by carcinomatous mastitis tending to ulceration and the high proliferation rate, compared to the localized stage of lung adenocarcinoma, a multidisciplinary decision was made to treat the more rapidly progressing disease, TNBC. In light of this, the importance of collecting clinical practice data to support the complex challenges we face daily is emphasized.

Triple-negative breast cancer (TNBC) represents a major challenge for clinical oncologists, due to lack of therapeutical targets deriving from hormone-receptors and/or HER2 receptor expression. Moreover, TNBC typically shows a more aggressive clinical behavior and less responsiveness to traditional chemotherapy. Last years, the clinical scenario improved thanks to the introduction of new therapeutical agents (such as immunotherapy for PD-L1 positive cancer or PARP inhibitors for germline mutated BRCA1/2 tumors) including antibody-drug conjugates (ADCs). Sacituzumab-govitecan (SG) was the first in class ADC able to demonstrate a statistically significant and clinically relevant benefit for all survival endpoints (including overall survival - OS) in advanced triple negative breast cancer, progressing on prior systemic therapy. The use of these new agents is particularly challenging in older patients, where efficacy and tolerability need to be balanced. Here, we describe a case of a 74-year-old patient with plurimetastatic triple-negative disease. SG has been administered as a second-line of therapy after local control of brain metastasis throughout radiotherapy and showed a durable response with a tolerable safety profile (nausea G2).

The clinical case described concerns a 56-years old woman with triple-negative breast cancer metastic to bone progressed with previous chemotherapy and immunotherapy. Our patient, treated in second line with sacituzumab govitecan, obtained prolonged disease control without severe toxicity e with good quality of life.

During the 2nd interregional CIPOMO conference (April 2026), Sicilian and Calabrian oncologists discussed healthcare issues, focusing on clinicians' needs and digital transition. A survey revealed that while physicians recognize the potential of AI and digital tools to improve clinical safety and continuity of care, major structural and organizational weaknesses persist. Indeed, 68.4% feel their departments cannot integrate digital tools without increasing workloads. Respondents demand less bureaucracy, better hospital-territory continuity, and strategic recognition. Crucially, 100% agree that doctors must retain final decision-making responsibility. Ultimately, addressing system fragility and burnout is essential before successful digital integration can occur.

The Res Foundation PDTA Net Observatory has been updated to include all regional care pathways approved up to 2025. This up-to-date overview of which regions and which disease are covered by these pathways is useful for understanding how the implementation of the community care reform is progressing in relation to the integrated management of chronic conditions and identifying areas where action can be taken to support this process.

This position paper examines the strategic value of clinical and outcome research data for the National Health Service, with a specific focus on the dual mandate of Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) and the role of Local Health Authorities as custodians of extensive Real World Data repositories. Although the European regulatory framework - represented by the GDPR (Art. 89) and the upcoming European Health Data Space (EHDS) - alongside the Italian Privacy Code (Art. 110), provides solid legal bases for the secondary use of health data for scientific purposes, a significant gap persists between the potential of these informational assets and their effective exploitation. The document, resulting from a multidisciplinary collaboration involving researchers, legal experts, decision-makers, Data Protection Officers, Ethics Committees, and patient representatives, identifies current operational criticalities and proposes three priority strategic directions. First, it is imperative to systematize research governance to optimize resource allocation by integrating privacy by design principles and promoting interoperability standards and Federated Learning architectures. Second, the paper advocates transparency in management processes, urging institutions to move beyond the ineffective paradigm of security through obscurity in favor of verifiable architectures and clear traceability of data flows. Finally, the systematic development of the data stewardship function is recommended. Rather than acting as a bureaucratic control, the data steward should provide strategic mentorship and high-level consultation, bridging scientific research needs and regulatory compliance requirements. In conclusion, personal data protection must not be perceived as a barrier to biomedical progress, but as an enabling framework based on shared responsibility, safeguarding patients' rights while ensuring high standards of research excellence.